314 related articles for article (PubMed ID: 10861074)
1. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.
Zhu LX; Sharma S; Stolina M; Gardner B; Roth MD; Tashkin DP; Dubinett SM
J Immunol; 2000 Jul; 165(1):373-80. PubMed ID: 10861074
[TBL] [Abstract][Full Text] [Related]
2. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function.
Sharma S; Stolina M; Lin Y; Gardner B; Miller PW; Kronenberg M; Dubinett SM
J Immunol; 1999 Nov; 163(9):5020-8. PubMed ID: 10528207
[TBL] [Abstract][Full Text] [Related]
3. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection.
Klein TW; Newton CA; Nakachi N; Friedman H
J Immunol; 2000 Jun; 164(12):6461-6. PubMed ID: 10843702
[TBL] [Abstract][Full Text] [Related]
4. delta 9-Tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila.
Klein TW; Newton C; Zhu W; Daaka Y; Friedman H
Proc Soc Exp Biol Med; 1995 Jul; 209(3):205-12. PubMed ID: 7777582
[TBL] [Abstract][Full Text] [Related]
5. Effects of delta-9-tetrahydrocannabinol on human immune function and host defense.
Roth MD; Baldwin GC; Tashkin DP
Chem Phys Lipids; 2002 Dec; 121(1-2):229-39. PubMed ID: 12505703
[TBL] [Abstract][Full Text] [Related]
6. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response.
McKallip RJ; Nagarkatti M; Nagarkatti PS
J Immunol; 2005 Mar; 174(6):3281-9. PubMed ID: 15749859
[TBL] [Abstract][Full Text] [Related]
7. Viral IL-10-induced immunosuppression requires Th2 cytokines and impairs APC function within the allograft.
Qin L; Ding Y; Tahara H; Bromberg JS
J Immunol; 2001 Feb; 166(4):2385-93. PubMed ID: 11160297
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid.
Recht LD; Salmonsen R; Rosetti R; Jang T; Pipia G; Kubiatowski T; Karim P; Ross AH; Zurier R; Litofsky NS; Burstein S
Biochem Pharmacol; 2001 Sep; 62(6):755-63. PubMed ID: 11551521
[TBL] [Abstract][Full Text] [Related]
9. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection.
Newton CA; Klein TW; Friedman H
Infect Immun; 1994 Sep; 62(9):4015-20. PubMed ID: 8063421
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
11. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
12. Delta 9-tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function.
Schatz AR; Koh WS; Kaminski NE
Immunopharmacology; 1993; 26(2):129-37. PubMed ID: 8282537
[TBL] [Abstract][Full Text] [Related]
13. CB(1) and CB(2) cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection.
Newton CA; Chou PJ; Perkins I; Klein TW
J Neuroimmune Pharmacol; 2009 Mar; 4(1):92-102. PubMed ID: 18792785
[TBL] [Abstract][Full Text] [Related]
14. IL-10 mediates sigma 1 receptor-dependent suppression of antitumor immunity.
Zhu LX; Sharma S; Gardner B; Escuadro B; Atianzar K; Tashkin DP; Dubinett SM
J Immunol; 2003 Apr; 170(7):3585-91. PubMed ID: 12646621
[TBL] [Abstract][Full Text] [Related]
15. Relationship of aging and cytokines to the immunomodulation by delta-9-tetrahydrocannabinol on murine lymphoid cells.
Snella E; Pross S; Friedman H
Int J Immunopharmacol; 1995 Dec; 17(12):1045-54. PubMed ID: 8964654
[TBL] [Abstract][Full Text] [Related]
16. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo.
Sharma S; Stolina M; Luo J; Strieter RM; Burdick M; Zhu LX; Batra RK; Dubinett SM
J Immunol; 2000 May; 164(9):4558-63. PubMed ID: 10779757
[TBL] [Abstract][Full Text] [Related]
17. Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta.
Gardner B; Zu LX; Sharma S; Liu Q; Makriyannis A; Tashkin DP; Dubinett SM
Biochem Biophys Res Commun; 2002 Jan; 290(1):91-6. PubMed ID: 11779138
[TBL] [Abstract][Full Text] [Related]
18. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.
McKallip RJ; Lombard C; Fisher M; Martin BR; Ryu S; Grant S; Nagarkatti PS; Nagarkatti M
Blood; 2002 Jul; 100(2):627-34. PubMed ID: 12091357
[TBL] [Abstract][Full Text] [Related]
19. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo.
McKallip RJ; Lombard C; Martin BR; Nagarkatti M; Nagarkatti PS
J Pharmacol Exp Ther; 2002 Aug; 302(2):451-65. PubMed ID: 12130702
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells.
Rao GK; Zhang W; Kaminski NE
J Leukoc Biol; 2004 May; 75(5):884-92. PubMed ID: 14966196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
